Bio Green Med Solution (BGMS) Common Equity (2010 - 2026)

Bio Green Med Solution (BGMS) has reported Common Equity for 17 consecutive years, with $6.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 120.77% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $6.8 million (up 120.77% YoY), while the FY2025 annual figure was $6.8 million, up 414.72% from the prior year.
• Common Equity eased to $6.8 million in Q1 2026 per BGMS's latest filing, from $6.8 million in the prior quarter.
• Across five years, Common Equity topped out at $33.8 million in Q1 2022 and bottomed at -$2.2 million in Q1 2024.
• Historically, Common Equity has averaged $8.6 million across 5 years, with a median of $6.7 million in 2023.
• Annual changes were most pronounced in 2024 — Common Equity plunged 458.15% — and 2025, when it surged 831.55%.
• Bio Green Med Solution's Common Equity stood at $15.9 million in 2022, then tumbled by 96.19% to $607000.0 in 2023, then slumped by 458.15% to -$2.2 million in 2024, then surged by 414.72% to $6.8 million in 2025, then declined by 1.2% to $6.8 million in 2026.
• Business Quant data shows BGMS's Common Equity at $6.8 million in Q1 2026, $6.8 million in Q4 2025, and $7.1 million in Q3 2025.